IF 14
PMID: 38614093 ↗Cisplatin
Catalog No.: GC11908Purity:>98.00%Synonyms: CDDP
Cisplatin, a platinum-containing anticancer drug, is one of the most commonly used cytotoxic agents for the treatment of a variety of solid malignant tumors.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 15663-27-1
10mM (in 1mL DMF)In Stock
$30.00
1
5mgIn Stock
$9.00
1
10mgIn Stock
$13.00
1
50mgIn Stock
$20.00
1
100mgIn Stock
$30.00
1
500mgIn Stock
$77.00
1
1gIn Stock
$130.00
1
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMF) | $30.00 | In Stock | 1 | |
| 5mg | $9.00 | In Stock | 1 | |
| 10mg | $13.00 | In Stock | 1 | |
| 50mg | $20.00 | In Stock | 1 | |
| 100mg | $30.00 | In Stock | 1 | |
| 500mg | $77.00 | In Stock | 1 | |
| 1g | $130.00 | In Stock | 1 |
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com
Citations
19 publicationsPublications from researchers using this productDescription
Cisplatin, a platinum-containing anticancer drug, is one of the most commonly used cytotoxic agents for the treatment of a variety of solid malignant tumors. Cisplatin generally binds with genomic DNA (gDNA) or mitochondrial DNA (mtDNA) to create DNA lesions, block the production of DNA, mRNA and proteins, arrest DNA replication, activate several transduction pathways which finally led to necrosis or apoptosis[1-2].
In vitro, Cisplatin (0-30μM; 12-24h) induced apoptosis in HeLa cells in a dose- and time-dependent manner[1]. Cisplatin (0-40μg/ml; 24h) inhibited melanoma cell growth in a dose-dependent manner, with IC50 at about 15μg/ml[3].
In vivo, Cisplatin (4mg/kg; i.p.; 3 times) inhibited tumor growth in a B16F0 melanoma-bearing mouse model[3]. Cisplatin (5mg/kg; i.p.; 2 weeks) can establish a mouse model of acute kidney injury, as evidenced by elevated levels of serum creatinine (SCr), blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin (NGAL), and nitrotyrosine[4].
References:
[1] Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275(50):39435-39443.
[2] Stordal B, et al. Understanding cisplatin resistance using cellular models. IUBMB Life. 2007 Nov;59(11):696-9.
[3] Park HR, Ju EJ, Jo SK, Jung U, Kim SH, Yee ST. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009;9:85. Published 2009 Mar 17.
[4] Noha Alassaf, et al. Autophagy and necroptosis in cisplatin-induced acute kidney injury: Recent advances regarding their role and therapeutic potential. Front Pharmacol. 2023 Jan 30:14:1103062.
Protocol
| Cell experiment [1]: | |
|
Cell lines |
Melanoma cell |
|
Preparation Method |
The melanoma cells were seeded on to 96-well plates at a density of 7×103 cells per well in 100μl of media. After incubation for 24 hours, cells were treated with various concentration of Cisplatin for 24 hours. After incubation, a CCK-8 solution was added to each well. |
|
Reaction Conditions |
0-40μg/ml; 24h |
|
Applications |
Cisplatin inhibited melanoma cell growth in a dose-dependent manner, with IC50 at about 15μg/ml. |
| Animal experiment [1]: | |
|
Animal models |
B16F0 melanoma-bearing mouse model |
|
Preparation Method |
B16F0 melanoma (5×105 cells/mouse) was inoculated into subcutaneous femoral left region of mice at 3 days before an initial injection of Cisplatin. Cisplatin was injected intraperitoneally at 4mg/kg on day 0, 7 and 14 (total three injections). On day 17 after initial injection of Cisplatin, mice were experimented, respectively, to evaluate tumor weight or tumor size. |
|
Dosage form |
4mg/kg; i.p.; 3 times |
|
Applications |
In the Cisplatin-injected group, tumor weight (2.97g (±1.29)) and size (6.3mm3 (±2.32)) were reduced significantly in comparison to the control group. |
References: [1] Park HR, Ju EJ, Jo SK, Jung U, Kim SH, Yee ST. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009;9:85. | |
Product Documents
Purity:>98.00%Appearance:A solid
Chemical Properties
CAS No.
15663-27-1
Synonyms
CDDP
Chemical Name
azane;dichloroplatinum(2+)
SMILES
N.N.Cl[Pt+2]Cl
Molecular Formula
Cl2H6N2Pt
Molecular Weight
300.05
Solubility
5 mg/mL in DMF (16.66 mM; DMSO can inactivate Cisplatin's activity), 1 mg/mL in Water (3.33 mM; DMSO can inactivate Cisplatin's activity)
Storage
4°C, protect from light
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
g/mol
Reviews
Review for Cisplatin
Rating: 5
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%